XML 74 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration and Other Agreements, Takeda (Details) - Takeda Pharmaceutical Company Limited (Takeda) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2014	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Takeda MGD010 Agreement
Collaboration and Other Agreements [Line Items]
Non-refundable upfront payment	$ 15,000,000
Amount allocated to agreement	$ 10,000,000
Expected period of development	24 months
Option exercise fee recognition period		8 months
Recognized revenue under agreement			$ 0	$ 2,100,000	$ 8,000,000
Milestone received					$ 3,000,000
Deferred revenue			$ 0	$ 0
Research Collaboration and License Option Agreement
Collaboration and Other Agreements [Line Items]
Amount allocated to agreement	$ 5,000,000

X

- Definition

Initial fee received from collaboration or license agreement.

+ References

No definition available.

+ Details

Name:	mgnx_NonRefundableUpfrontFees
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Refers to option exercise fee recognition period.

+ References

No definition available.

+ Details

Name:	mgnx_OptionExerciseFeeRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Portion of upfront fee allocated to agreement.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontFeeAllocatedToAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Refers to upfront payment recognition period.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=mgnx_TakedaMGD010AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: